Thursday, June 28, 2018 4:34:57 PM
Theralase Sustains IP Strength with Newly Issued US Patents Since our Original Report, with TLD-1433 Well Patented Until at Least 2033
But for now, TLD-1433’s contribution to our revenue/EBITDA forecasts is solely driven by our royalty revenue projections in BCG-refractory NMIBC only.
http://67.212.93.22/research/content/20170905TLT%20final.pdf
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM